GERN - Geron Corporation
| Previous Close | 1.5100 |
| Open | 1.5400 |
| Bid | 0.0000 x 21500 |
| Ask | 0.0000 x 40000 |
| Day's Range | 1.5050 - 1.5500 |
| 52 Week Range | 0.9500 - 2.1400 |
| Volume | 1,280,171 |
| Avg. Volume | 1,453,550 |
| Market Cap | 305.66M |
| Beta (3Y Monthly) | 2.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | Nov. 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.80 |
- Zacks
Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Geron Announces Appointment of New Executive to Focus on Corporate Strategy
Geron Corporation (GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. “We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
- Zacks
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- GlobeNewswire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20, 2019 at an exercise price of $1.36 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
- Thomson Reuters StreetEvents
Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT
Q3 2019 Geron Corp Earnings Call
- Zacks
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
- GlobeNewswire
Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
Geron Corporation (GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The Company ended the third quarter with $159.3 million in cash and marketable securities. “Geron has continued to execute on its 2019 development plans,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
- GlobeNewswire
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
MENLO PARK, Calif., Nov. 06, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase.
- Simply Wall St.
What Type Of Shareholder Owns Geron Corporation's (NASDAQ:GERN)?
A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large...
- Zacks
Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Geron to Announce Third Quarter Financial Results on November 6, 2019
Geron Corporation (GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call on Thursday, November 7 at 8:00 a.m. ET to discuss the financial results as well as recent events. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
- Zacks
Geron Starts Enrollment in Phase III MDS Study on Imetelstat
Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
- GlobeNewswire
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Geron Corporation (GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “Patients with lower risk MDS become dependent on serial transfusions which leads to iron overload, heart and kidney complications, decreases in quality of life and shorter overall survival. Reducing transfusion burden and achieving transfusion independence remain significant medical needs for this disease,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer.
- Zacks
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
- GlobeNewswire
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
Geron Corporation (GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. The Fast Track designation includes patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera.
- GlobeNewswire
Geron to Present at 2019 Cantor Global Healthcare Conference
MENLO PARK, Calif., Sept. 26, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
- Simply Wall St.
Does Geron Corporation's (NASDAQ:GERN) CEO Pay Compare Well With Peers?
Chip Scarlett has been the CEO of Geron Corporation (NASDAQ:GERN) since 2011. This analysis aims first to contrast CEO...
- Zacks
Why Is Geron (GERN) Up 21.7% Since Last Earnings Report?
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
- Simply Wall St.
A Spotlight On Geron Corporation's (NASDAQ:GERN) Fundamentals
Geron Corporation (NASDAQ:GERN) is a stock with outstanding fundamental characteristics. When we build an investment...
- GlobeNewswire
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
- Thomson Reuters StreetEvents
Edited Transcript of GERN earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Geron Corp Earnings Call
Motley FoolGeron Corporation (Delaware) (GERN) Q2 2019 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2019.
